UTv Videos

"We're pleased to report that there was a strong prognostic signal we found with the overall cohort," says Charles Parker, MD.

"If you disrupt a good patient-physician relationship to the point where patients actually don't seek the care they need, that's obviously very problematic," says Raveen Syan, MD, FPMRS.

"The main highlight of this trial was the complete response rate, which was around 22%," says , Guru P. Sonpavde, MD.

"The surprise to me was the grade 3/4 adverse events [were] better with 177Lu-PSMA-617, SAEs [were] better with 177Lu-PSMA-617, and dose adjustments [were] better with 177Lu-PSMA-617," says Oliver Sartor, MD.

Toni K. Choueiri, MD, highlights data from the phase 2 LITESPARK-003 trial, which were presented at the 2023 ESMO Congress.

"TAR-210 is set to become a potentially new option for this patient population after failure of BCG treatment," says Andrea Necchi, MD.

“In other words, there's a 72% less chance of recurrence with oral erdafitinib than with standard of care. The problem is tolerability,” says James W.F. Catto, PhD, FRCS.

“The recommended phase 2 dose was dose level 2, so 8 mg/kg of SG with EV 1.25mg/kg,” says Bradley McGregor, MD.

“We have not previously managed to beat first-line chemotherapy in any trial in unselected first-line urothelial cancer, so this is a big step in that direction,” says Thomas B. Powles, MBBS, MRCP, MD.

“This is the first study in upper tract urothelial carcinoma to show that ctDNA may be used to refine clinical staging and prognosis in these patients prior to surgery,” says Heather L. Huelster, MD.

“In fact, we actually found that there were more lawsuits that were directed at physicians who did not recommend active surveillance when it was an appropriate treatment strategy,” says Timothy J. Daskivich, MD, MSHPM.

“Concerningly, when we look at our community population, more than a third just didn't know where to go,” says Raveen Syan, MD, FPMRS.

“Where we are with this, I think that our results do not support the theory that agonists have a higher cardiovascular risk than antagonists,” says E. David Crawford, MD.

"In this study, we sought to evaluate the utility of a non-invasive biomarker—ctDNA—in predicting muscle-invasive and non–organ-confined staging of upper tract urothelial carcinoma," says Heather L. Huelster, MD.

“Providers can use this information to counsel patients that that initial sticker shock goes away once you stick with that medication,” says Katherine Shapiro, MD.

"We're calling upon urologists and primary care physicians to start the conversation and normalize discussion about erectile dysfunction with their patients before they fall through the cracks and ended up victims of these predatory online services," says Jack Vercnocke, MD.

"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.

"The main thing that we were surprised by was that at this point in time, ChatGPT couldn't give us consistent results," says Athena Barrett.

"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.

“When you're talking about Medicare patients who are on multiple medications, and this is not the only thing that they're taking, to pay over $100 for 1 medication is sometimes not possible,” says Katherine Shapiro, MD.

“Company 3 was the most surprising; the cost was $5220 per year for 10 20-mg [tadalafil] pills per month,” says Jack Vercnocke, MD.

"It's really a monumental change for patients, and it is a massive win for our health care system," says Benjamin Pockros, MD.

“We also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC,” says Nirmish Singla, MD, MSc.

Alexandra Sokolova, MD, explains the importance of genetic testing for patients with high-risk localized and advanced prostate cancer, as well as for their high-risk family members.

“Our aim overall is to describe Medicare Part D prescription drug coverage and use of prior authorization and step therapy for these medications,” says Katherine Shapiro, MD.

"We really have to think beyond just the individual health impact to understand what's underlying these disparities," says Raveen Syan, MD, FPMRS.

“I think this study gives us actual numbers, so we can have a sense of how much time people will take off over time,” says Samuel L. Washington, MD, MAS.